| First Name: |
Donald |
| Last Name: |
Harting |
| Email: |
don@hartingcom.com |
| Phone: |
(610) 635-5303
|
| Address: |
Downingtown, PA, 19335
|
| Credentials: |
MA, MS, ELS, CHCP |
| What type of professional services do you provide? |
Developing interactive case studies, Developing slide decks and/or monographs, Graphics, illustration, and design, Learning goals and objective development, Outcomes measurement, Program development and implementation, Writing needs assessments, Other |
| Other professional services: |
I also write and edit patient simulations, test questions, peer-reviewed journal articles, posters, charts, tables, and outcome reports. |
| How many years of experience do you have in healthcare CPD? |
More than 10 years |
| In which therapeutic areas do you have previous experience? |
Cardiovascular disorders, Diabetes/endocrinology, Hematology/Oncology, Infectious disease, Neurology/MS, Rheumatology |
| What types of accreditation and individual activity approvals are you looking for? |
|
| Other therapeutic areas: |
|
| Describe your expertise: |
Since 2009, my needs assessments have been instrumental in winning more than $4.6 million for accredited continuing education, mostly in oncology. My consulting clients are mostly private med-ed companies. Funding has come from major pharmaceutical companies such as Boehringer-Ingelheim, Celgene, Genentech, GlaxoSmithKline, Janssen Scientific, Pfizer, Takeda, and many others.
Some topics of recently funded educational grants include aggressive lymphomas, biosimilars, HR+/HER2- breast cancer, new hematology drugs, new solid tumor drugs especially precision targeted agents and immune checkpoint inhibitors, BCMA-targeted agents in multiple myeloma, and early diagnosis in multiple myeloma.
I have written several needs assessment related to COVID-19, including COVID-19 in immuno-compromised rheumatology patients; COVID-19 in immuno-compromised IBD patients; and COVID-19 in patients with multiple sclerosis.
Other recent assignments include oncology biomarkers, new oncology drugs, anti-TNF biosimilars in IBD, anti-VEGF biosimilars in ophthalmology, maintenance therapy in acute myeloid leukemia, recent advances in chronic lymphocytic leukemia, EGFR-targeted agents in non-small cell lung cancer, graft-versus-host disease, and advances in hepatocellular carcinoma (HCC).
In addition to writing NAs, I also work with faculty to develop various types of educational materials including slide decks, online manuscripts, interactive monographs, case studies, test questions, posters, and outcome reports. |
| Brief biography: |
I am a skilled and experienced medical writer who specializes in continuing education for the health professions. I am also a lifelong learner, having earned a bachelor's degree in liberal arts from Harvard in 1978, a master's degree in journalism in 1992, and a master's degree in biology in 2018. As a newspaper reporter I won awards for public service and investigative projects. I transitioned into medical writing with help from the American Medical Writers Association, of which I remain an active member. I earned permanent certification as a board-certified editor in the life sciences (ELS) in 2008. I earned the CHCP credential in 2011 and am re-certified through 2021.
Writing needs assessments (NAs) forms the foundation of my consulting practice. I started writing NAs in 2008 for a med-ed company that specialized in oncology. My background in oncology deepened during a 15-month sojourn in the continuing education department of the National Comprehensive Cancer Network.
Since 2014, I have been working with co-investigators and consultants to conduct survey research on best practices for writing NAs. You may have seen our 3 posters at the most recent Alliance meeting in San Francisco. We also published an article in the Almanac. |
| Where should someone go online to find more information about your skills and abilities? |
https://www.linkedin.com/in/donald-harting-ma-ms-els-chcp-817b80b/
|
